Therapeutic Observation of Wheat-sized Moxibustion in Assisting the Treatment of Mild—to-moderate Persistent Chronic Bronchial Asthma in the Elderly
10.13460/j.issn.1005-0957.2017.12.1387
- VernacularTitle:麦粒灸辅助治疗轻中度老年支气管哮喘慢性持续期疗效观察
- Author:
ying Xue CUI
1
;
yan Ding BI
Author Information
1. 杭州市中医院
- Keywords:
Asthma;
Wheat-sized moxibustion;
Pulmonary function test;
Asthma control test;
Asthma quality of life questionnaire
- From:
Shanghai Journal of Acupuncture and Moxibustion
2017;36(12):1387-1390
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of wheat-sized moxibustion in assisting the treatment of mild—to-moderate persistent chronic bronchial asthma in the elderly with Salmeterol xinafoate and fluticasone propionate aerosol. Method Eighty-four old patients with mild—to-moderate persistent chronic bronchial asthma were randomized into an observation group and a control group by using the random number table, 42 each. The control group was given Salmeterol xinafoate and fluticasone propionate aerosol, 1 inhalation each time, twice a day;the observation group was additionally given wheat-sized moxibustion by selecting Pishu (BL20), Feishu (BL13) and Geshu (BL17), twice a week. The two groups were both treated for 2 months. Before and after the intervention, Asthma Control Test (ACT), Asthma Quality of Life Questionnaire (AQLQ), and pulmonary function parameters [peak expiratory flow (PEF), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC)] were observed, and the clinical efficacies were compared. Result The total effective rate was 92.9% in the observation group versus 78.6% in the control group, and the difference was statistically significant (P<0.05); the ACT and AQLQ scores, as well as PEF, FEV1 and FVC were significantly increased after the intervention in both groups (P<0.05); after the treatment, the improvement in the observation group was significantly superior to that in the control group (P<0.05). Conclusion Wheat-sized moxibustion is effective in assisting the treatment of mild-to-moderate persistent chronic bronchial asthma in the elderly with Salmeterol xinafoate and fluticasone propionate aerosol. It can effectively controlasthma and enhance the quality of life.
